ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103

Its studies are led by ABL Bio.

Furthest: phase 2, since Aug 8, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ABL Bio22 open or runningphase 2since Aug 8, 2025Nov 2, 2023Dec 2, 2027phase 2 · NCT07158918

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT06126666 · 96 planned · South Korea
  2. Aug 8, 2025Phase 2 study in Solid TumorsNCT07158918 · 65 planned · United States, Australia, South Korea

Ahead

  1. Dec 2, 2027Primary completion: phase 2 study in Solid TumorsNCT07158918

TargetBeta

“A T-cell engaging (TCE) bispecific antibody against both the tumor-associated antigen (TAA) B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07158918Solid Tumors · United States, Australia, South Korea2RecruitingDec 2, 202765
NCT06126666Advanced Solid Tumor · South Korea1RecruitingDec 30, 202596

How it is read

Names in the registry

  • “ABL103”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.